anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Muscle relaxants are integral part of modern anesthesia. They optimize intubating conditions, reduce laryngeal trauma and improve operating conditions. Drawback is a possible pharmacological (muscle relaxing) effect of these drugs beyond the end of the operation (i.e. post-operative residual curarization: PORC). Reportedly about 30% of all patients who received muscle relaxants show signs of PORC when arriving in the post-anesthesia care unit. PORC comprises the risk of impaired post-operative fine motor and coordinative skills with a possible impairment of swallowing pharyngeal secretions with an increased risk of aspiration after extubation. Possible deleterious effects of this could be pneumonia, bronchitis, myocardial infarction, cardiac insufficiency, stroke or re-operation.

In order to avoid PORC patients with residual neuromuscular block receive a muscle relaxant antagonist from the anesthesiologist at the end of the operation. However, these drugs (neostigmine, pyridostigmine, etc.) from the class of cholinesterase inhibitors have unwanted effects such as bradycardia, increased gastro-intestinal motility, post-operative nausea and vomiting, salivation etc. To decrease these unwanted side effects cholinesterase inhibitors have to be given in combination with parasympatholyics e.g. atropine or glycopyrrolate with their own spectrum of unwanted side effects.

From October 2008 on, Sugammadex, a completely new reversal drug was introduced in to clinical practice. Sugammadex, is a modified γ-cyclodextrine able to specifically bind rocuronium (a steroidal muscle relaxant). The complex is eliminated via the kidneys. However, all studies so far have focussed on reversal of profound or deep neuromuscular blockade. This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.2) with different doses of either the neostigmine or sugammadex.
Participants in the lab-based stretching group will receive 4 months of stretching in the lab (2 times per week for 16 weeks, total 32 sessions).The stretching program will include progressive stretches for upper and lower-limb muscles, core and back muscles followed by a cool-down of 10 mins including relaxation and breathing exercises. Stretching exercises will include single and multi-joint stretches designed to target improvements in performance of daily living activities.
The present invention relates to a method for the segmentation and processing of dental images for diagnosing, predicting, or managing oral conditions. The present invention determines the state of the occlusal surface and the incisal surface in an upper and lower jaw dental picture, which is not limited to photographs of the entire upper and lower jaw, and is also applicable to photographs photographed of partial teeth or buccal surfaces. The present invention can be applied to photographs photographed through various types of oral camera imaging systems (X-ray and CT). The present invention marks a teeth area in the photograph photographed inside the oral cavity, expands the individual tooth area secured after determining the position of the individual tooth, analyzes the state of the teeth and expresses the state numerically. The intraoral photograph is applied according to the lighting condition, the type of teeth, and the condition of the teeth (cavity, peeling, and discoloration). The present invention performs the task of removing such noise because the noise from other saliva, light reflection, food, orthodontics, and dental equipment interferes with accurate determination of the tooth area.
Dosage should generally be started at the lowest recommended dose and increased gradually based on patient response.

†Concentrations up to 10 times greater have been used when limitation of volume is essential.

††Rates over 30 mcg per minute have been used in advanced stages of shock. Adjust the rate of infusion based on heart rate, central venous pressure, systemic blood pressure, and urine flow. If the heart rate exceeds 110 beats per minute, consider decreasing or temporarily discontinuing the infusion.

There are no well-controlled studies in children to establish appropriate dosing; however, the American Heart Association recommends an initial infusion rate of 0.1 mcg/kg/min, with the usual range being 0.1 mcg/kg/min to 1 mcg/kg/min.
In this study, we aim to investigate the role of enolase 1 (ENO1) in osteoarthritis (OA) pathogenic process and to uncover the underlying mechanism. To this end, we used IL-1β to induce an in vitro OA‑like chondrocyte model in human immortalized chondrocyte C-28/I2 cells. We manipulated the expression of ENO1 and cytokine receptor-like factor 1 (CRLF1) in IL-1β-induced C-28/I2 cells using siRNA and/or overexpression and tested their effects on IL-1β-induced pathologies including cell viability, apoptosis and inflammatory cytokine levels (IL-6 and TNF-α), and the expression of extracellular matrix-related enzymes and major mediators in the NF-κB signaling pathway (p-p65, p65, p-IκBα and IκBα). We used co-immunoprecipitation and immunofluorescence imaging to study a possible binding between ENO1 and CRLF1. Our data showed that IL-1β induction elevated ENO1 and CRLF1 expression in C-28/I2 cells. Silencing ENO1 or CRLF1 inhibited the IL-1β-induced cell viability damage, apoptosis, inflammation, and extracellular matrix degradation. The inhibitory effect of silencing ENO1 was reversed by CRLF1 overexpression, suggesting a functional connection between ENO1 and CRLF1, which could be attributed to a binding between these two partners. Our study could help validate the role of ENO1 in OA pathogenies and identify novel therapeutic targets for OA treatment.
Arsenic trioxide injection is a sterile injectable solution of arsenic trioxide. The molecular formula of arsenic trioxide in the solid state is As2O3, with a molecular weight of 197.8 and the following structural formula: 

Arsenic trioxide injection is available in 10 mL, single-dose vials containing 10 mg of arsenic trioxide. Arsenic trioxide injection is formulated as a sterile, nonpyrogenic, clear solution of arsenic trioxide in water for injection using sodium hydroxide and dilute hydrochloric acid to adjust to pH 8. Arsenic trioxide injection is preservative-free. Arsenic trioxide, the active ingredient, is present at a concentration of 1.0 mg/mL. Inactive ingredients and their respective approximate concentrations are sodium hydroxide (1.2 mg/mL) for solubilization, and sodium hydroxide and hydrochloric acid for pH adjustment to pH 8.
Methods and systems for tracking movement include performing person detection in frames from multiple video streams to identify detection images. Visual and location information from the detection images are combined to generate scores for pairs of detection images across the multiple video streams and across frames of respective video streams. A pairwise detection graph is generated using the detection images as nodes and the scores as weighted edges. Movement of an individual is tracked based a constrained answer set programming problem, with constraints determined based on matching scores and logical assumptions. An action responsive to the tracked movement is performed. Tracking of movement of a patient in a healthcare facility can be used to inform treatment decisions by healthcare professionals.
PURPOSE: Provided is Provided is a skin whitening cosmetic containing, as an active ingredient, one of Phyllanthus ussuriensis extract, Alocasia cucullata Schott extract or their mixture having inhibiting effect on melanin generation. The Phyllanthus ussuriensis extract, and Alocasia cucullata Schott extract are natural products and are thus applied to the skin safely without adverse effect. They are also inhibits the generation of melanin to prevent pigmentation on the skin. Therefore, the composition containing them is useful for discoloration on the face, freckles and skin whitening. CONSTITUTION: A skin whitening cosmetic characteristically contains, as an active ingredient, one of Phyllanthus ussuriensis extract, Alocasia cucullata Schott extract or their mixture in the amount of 0.0001-10.0 dry wt.%, based on the total weight of the composition. The extraction solvent is selected from the group consisting of water, C1-4 lower alcohol, ethylacetate and acetone.
FIELD: organic chemistry, heterocyclic compounds, pharmacy. SUBSTANCE: invention relates to novel guanidyl heterocyclic compounds of the formula (I)   where R 1  means H, alkyl or absent; when R 1  absent then bond (a) is a double one, D means CR 2  where R 2  is taken among H, alkyl, halogen atom, or when B means CR 3  then D can mean N; B means NR 9 , CR 3 =CR 8 , CR 3 , S where R 9  means H, alkyl, alkenyl or alkynyl and where R 3  and R 8  are taken among H, alkyl, alkenyl, alkynyl or cyano-group; each of R 4 , R 5 , R 6  is taken independently among H, alkyl, alkenyl, alkynyl, cyano-group or NH=C(=NR 10 )NHR 11  (guanidinyl); R 10  and R 11  are taken among H, methyl and ethyl and where only one of R 1 , R 5  and R 6  means guanidinyl; R 7  is taken among H, alkyl, alkenyl, alkynyl and halogen atom. These compounds show agonistic activity with respect to alpha-2 adrenoceptors and therefore in common with pharmaceutically acceptable carrier can form pharmaceutical composition. Invention relates also to method of activation of alpha-2 adrenoceptors for prophylaxis and treatment of diseases when agonists of alpha-2 adrenoceptors are effective agents for diseases relief. EFFECT: valuable medicinal properties of compounds. 7 cl
Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the content of hydromorphone and hydromorphone-3-glucuronide (the main metabolite) was detected by quantitative liquid chromatography tandem mass spectrometry. And then a population pharmacokinetic model of hydromorphone in patients under ECMO was established.
PURPOSE: To obtain a sustained release preparation by combining a readily water-soluble agent with a glycerol fatty acid ester and a water-insoluble substance. CONSTITUTION: This sustained release preparation is obtained by properly mixing a readily water-soluble agent (e.g. disopyramide sulfate), a glycerol fatty acid ester (e.g. stearic acid monodiglyceride) and a water-insoluble substance (e.g. methacrylic acid copolymer). The preparation is properly mixed with various additives such as polyvinylpyrrolidone, magnesium stearate, hydroxypropyl methyl cellulose, titanium oxide and macrogol 6,000 useful in pharmaceutical preparation of an ordinary medicine and pharmaceutically manufactured into a tablet, granule, fine granule or capsule by a conventional procedure. The sustained release preparation is mixed with 1-30wt.% of the water-soluble agent and 1-50wt.% of the glycerol fatty acid ester.  The sustained release preparation is readily soluble in water, rapidly absorbed in an organism, suppresses absorption of the readily water-soluble agent, makes the agent gradually be absorbed in an organism, has no moisture absorption and is useful as a stable sustained- release preparation.
Although Mozambique has so far had few confirmed cases of COVID19, it is unknown if low testing rates and other factors such as the warm climatic conditions may explain the apparently low spread of the virus. The present proposal aims to rapidly gain an understanding of the epidemic curve and natural history of SARS-CoV-2 in a rural area in southern Mozambique through a series of epidemiological indicators obtained at both the health facility and community levels, so as to provide evidence-based recommendations for managing and mitigating the COVID19 epidemic. Age-specific incidence of severe COVID-19 obtained at health facilities during a period of 15 months together with seroprevalence data obtained from the community will be used to determine SARS-CoV-2 reproduction number and effects of interventions through mathematical modeling. Viral, serological, and clinical progression will be assessed in a longitudinal cohort of symptomatic SARS-CoV-2 infected individuals. Community awareness of COVID-19 and of project aims will be fostered through engagement activities among community leaders and members. COVID-19 surveillance capacities in Mozambique will be strengthened by developing SARS-CoV-2 diagnostic approaches (molecular testing and an innovative immunoassay to detect antibodies against the virus), as well as SARS-CoV-2 genome sequencing approaches to identify transmission chains. Finally, the project will pursue the creation of a bank of serum, virus materials, and data which will be open for immediate public health purposes, including the development of point-of-care diagnostic tests. This project will be coordinated by the Manhiça Health Research Centre (Mozambique) in conjunction with the Barcelona Institute for Global Health (Spain), which will lead the transfer of molecular and immunological tools to the Mozambican research center. Imperial College will provide the modeling expertise to derive metrics of transmission, and INS the expertise to conduct quality control of laboratory determinations as well as dissemination and networking with the Ministry of Health in Mozambique. Four WPs will comprise the main research tasks, including COVID-19 surveillance (WP1), Laboratory determinations (WP2), Contact tracing and community awareness (WP3), Modelling (WP4), as well as two cross-cutting WPs related to Capacity-building (WP5) and Scientific coordination, management, networking \& dissemination (WP6). We expect this 21-month project will increase the level of preparedness, alertness, and response in Mozambique
BACKGROUND: Psoriasis is a chronic, inflammatory and recurrent skin disease. Xiao-Chai-Hu Decoction (XCHD) has shown good effects against some inflammatory diseases and cancers. However, the pharmacological effect and mechanisms of XCHD on psoriasis are not yet clear.
OBJECTIVE: To uncover the effect and mechanisms of XCHD on psoriasis by integrating network pharmacology, molecular docking, and in vivo experiments.
METHODS: The active ingredients and corresponding targets of XCHD were screened through Traditional Chinese Medicine Systems Pharmacology Database and Analysis (TCMSP) and Traditional Chinese Medicine Integrated Database (TCMID). Differentially expressed genes (DEGs) of psoriasis were obtained from the gene expression omnibus (GEO) database. The XCHD-psoriasis intersection targets were obtained by intersecting XCHD targets, and DEGs were used to establish the "herb-active ingredient-target" network and Protein-Protein Interaction (PPI) Network. The hub targets were identified based on the PPI network by Cytoscape software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed next. Molecular docking was executed via AutoDockTools-1.5.6. Finally, in vivo experiments were carried out further to validate the therapeutic effects of XCHD on psoriasis.
RESULTS: 58 active components and 219 targets of XCHD were screened. 4 top-active components (quercetin, baicalein, wogonin and kaempferol) and 7 hub targets (IL1B, CXCL8, CCND1, FOS, MMP9, STAT1 and CCL2) were identified. GO and KEGG pathway enrichment analyses indicated that the TNF signaling pathway, IL-17 signaling pathway and several pathways were involved. Molecular docking results indicated that hub genes had a good affinity to the corresponding key compounds. In imiquimod (IMQ)-induced psoriasis mouse models, XCHD could significantly improve psoriasis-like skin lesions, downregulate KRT17 and Ki67, and inhibit inflammation cytokines and VEGF.
CONCLUSION: XCHD showed the therapeutic effect on psoriasis by regulating keratinocyte differentiation, and suppressing inflammation and angiogenesis, which provided a theoretical basis for further experiments and clinical research.
Phone design features cause different problems on body mechanics and musculoskeletal system. With the use of smartphones, people tend to maintain incorrect postures for long periods of time, which increases tension in the body. This situation causes complaints such as cervical disc herniation, tingling complaints in different body parts, overuse injuries, Upper Crosses syndrome, and carpal tunnel syndrome. On the other hand, the use of smartphones is increasing among students for reasons such as providing students with freedom of time and space, increasing the speed of teaching and learning, supporting one-on-one learning, and increasing the number of ideas produced by encouraging a group discussion environment.

Mobile phones have different uses in different disciplines, and this encourages long-term use. Although many musculoskeletal system structures can be affected by incorrect postures due to the long-term use of smart mobile phones, it is thought that the upper extremity is most affected. Therefore, the aim of our study is to investigate the relationship between smartphone dimensions and hand anthropometric measurements and upper extremity pain and functions in order to raise awareness when purchasing mobile phones that match users' hand sizes for optimum comfort and use.
OBJECTIVE: This study aimed to map the characteristics and effects of vocal training approaches in individuals with healthy voice.
METHODS: This is a scoping review based on three research questions: What are the interventions used for vocal training of individuals with healthy voice? What are their prescription parameters? What are their effects? The search was conducted electronically in the databases of Embase, Lilacs, Medline, Scopus, and Web of Science. The study selection was based on the reading of titles, abstracts, and full text, applying the eligibility criteria. Data related to the characteristics of the publication, sample, and intervention were extracted. Measures/outcomes and results were also extracted. Quantitative synthesis was performed, and the results were presented in descriptive format.
RESULTS: In total, 221 studies were identified during the search, of which 23 were selected. The most frequently used approach in the vocal training of individuals with healthy voice was the Semi-Occluded Vocal Tract Exercise (SOVTE), mainly with tube and straw phonation. Many studies have focused on the immediate effect, with varying dosages. The main outcome measures were acoustic analysis, aerodynamic evaluation, electroglotography, and vocal self-assessment. Positive effects were mainly observed on aerodynamic and acoustic parameters. Only one study reported negative results in the self-assessment.
CONCLUSION: The SOVTE is most frequently performed to provide an immediate effect in the acoustic analysis and has also demonstrated positive effects on vocal self-assessment. Medium and long-term effects and dosages are rarely reported and should be also investigated.
Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
The invention concerns the eukaryotic transcript factor 17.38 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes the eukaryotic transcript factor 17.38.
Table 2 lists adverse events that occurred in 2 placebo-controlled clinical trials evaluating patients who took at least 1 dose of study drug. Only events that occurred at a frequency of 2% or more with TREXIMET and were more frequent than in the placebo group are included in Table 2. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.

Other events that occurred in more than 1% of patients receiving TREXIMET and occurred at a frequency greater than the placebo group included asthenia, feeling hot, muscle tightness, and palpitations.

TREXIMET was generally well tolerated. Most adverse reactions were mild and transient. The incidence of adverse events in controlled clinical trials was not affected by gender or age of the patients. There were insufficient data to assess the impact of race on the incidence of adverse events.
Patients in the intervention group were monitored with a tele-nursing application based on Orem's Self-Care Theory, and training and counseling were provided for 6 weeks after discharge. Post-discharge interviews were conducted by resercher via phone call and video conference (zoom, WhatsApp, etc.). The video conference method was presented to the patient's preference and the decision was made together. The interview with each patient lasted an average of 30 minutes. Patients in the intervention group were sent infographics prepared in line with the theory, including the interview content and suggestions after each interview. The study focuses on post-discharge tele-nursing practice follow-up outcomes. Baseline data were collected at the hospital on the 2nd and 3rd postoperative day. Post-discharge data were collected on the 7th-10th day, 18th-21st day and 40th-45th day.
Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.
Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A\*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
Over 950 patients received amlodipine and benazepril hydrochloride once-daily in 6 double-blind, placebo-controlled studies. The antihypertensive effect of a single dose persisted for 24 hours, with peak reductions achieved 2 to 8 hours after dosing. 

Once-daily doses of benazepril/amlodipine using benazepril doses of 10 to 20 mg and amlodipine doses of 2.5 mg to 10 mg decreased seated pressure (systolic/diastolic) 24 hours after dosing by about 10 to 25/6 to 13 mmHg.

In 2 studies in patients not adequately controlled on either benazepril 40 mg alone (n=329) or amlodipine 10 mg alone (n=812) once-daily doses of amlodipine and benazepril hydrochloride 10/40 mg further decreased seated blood pressure compared to the respective monotherapy alone. 

Combination therapy was effective in blacks and nonblacks. Both components contributed to the antihypertensive efficacy in nonblacks, but virtually all of the antihypertensive effect in blacks could be attributed to the amlodipine component. Among nonblack patients in placebo-controlled trials comparing amlodipine and benazepril hydrochloride to the individual components, the blood pressure lowering effects of the combination were shown to be additive and in some cases synergistic. 

During chronic therapy with amlodipine and benazepril hydrochloride, the maximum reduction in blood pressure with any given dose is generally achieved after 1 to 2 weeks. The antihypertensive effects of amlodipine and benazepril hydrochloride have continued during therapy for at least 1 year. Abrupt withdrawal of amlodipine and benazepril hydrochloride has not been associated with a rapid increase in blood pressure.